| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
KaVo Kerr is a dental equipment manufacturer group that was spun off from Danaher Corporation.
Vincerx Pharma is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer.
Visit the orthopedic surgeons and spine specialists at Envision Ortho, serving patients in Atlanta, Augusta, and Savannah, Georgia.
MCR American Pharmaceuticals, Inc. was established in 1991. Our product line consists of Allfen, Ambifed, Ambi, Maxifed, Maxinate, Maxiphen, Promacet and Time-Hist QD. Our sales representatives are located throughout the United States. We will continue